New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
